

# John B Kostis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2555140/publications.pdf>

Version: 2024-02-01

64  
papers

3,545  
citations

361045

20  
h-index

149479

56  
g-index

65  
all docs

65  
docs citations

65  
times ranked

4507  
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of integrated clinical safety data of tadalafil in patients receiving concomitant antihypertensive medications. <i>Journal of Clinical Hypertension</i> , 2022, , .	1.0	5
2	Relation of Socioeconomic Status to 1-Year Readmission and Mortality in Patients With Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2022, 175, 19-25.	0.7	2
3	The Benefits of Intensive Versus Standard Blood Pressure Treatment According to Fine Particulate Matter Air Pollution Exposure. <i>Hypertension</i> , 2021, 77, 813-822.	1.3	13
4	Monotherapy treatment with chlorthalidone or amlodipine in the systolic blood pressure intervention trial (SPRINT). <i>Journal of Clinical Hypertension</i> , 2021, 23, 1335-1343.	1.0	2
5	Critical Question in Cardiovascular Risk: Can we use clinical trials to improve the outcomes of patients with hypertension?. <i>International Journal of Cardiology Cardiovascular Risk and Prevention</i> , 2021, 11, 200108.	0.4	0
6	Prediction of stroke using an algorithm to estimate arterial stiffness. <i>International Journal of Cardiology Cardiovascular Risk and Prevention</i> , 2021, 11, 200114.	0.4	1
7	Effect of Intensive vs Standard Blood Pressure Treatment Upon Erectile Function in Hypertensive Men: Findings From the Systolic Blood Pressure Intervention Trial. <i>Journal of Sexual Medicine</i> , 2020, 17, 238-248.	0.3	7
8	Use of advanced statistical techniques to predict all-cause mortality in the Systolic Blood Pressure Intervention Trial. <i>International Journal of Cardiology: Hypertension</i> , 2020, 7, 100053.	2.2	0
9	Readmission and mortality among heart failure patients with history of hypertension in a statewide database. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1263-1274.	1.0	5
10	Limitations of Randomized Clinical Trials. <i>American Journal of Cardiology</i> , 2020, 129, 109-115.	0.7	29
11	The Legacy Effect in Treating Hypercholesterolemia. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2020, 25, 291-298.	1.0	4
12	Meta-Analysis of Usefulness of Treatment of Hypercholesterolemia With Statins for Primary Prevention in Patients Older Than 75 Years. <i>American Journal of Cardiology</i> , 2020, 125, 1154-1157.	0.7	11
13	Uses and opportunities for machine learning in hypertension research. <i>International Journal of Cardiology: Hypertension</i> , 2020, 5, 100027.	2.2	15
14	Blood pressure levels for patients with acute coronary syndromes. <i>Journal of Clinical Hypertension</i> , 2019, 21, 1144-1144.	1.0	0
15	Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2019, 24, 397-397.	1.0	0
16	Relation Between Statewide Hospital Performance Reports on Myocardial Infarction and Cardiovascular Outcomes. <i>American Journal of Cardiology</i> , 2019, 123, 1587-1594.	0.7	5
17	Statins and Erectile Dysfunction. <i>World Journal of Men's Health</i> , 2019, 37, 1.	1.7	12
18	Effect of cholesterol lowering with statins orÂaproprotein convertase subtilisin/kexin type 9 antibodies on cataracts: A meta-analysis. <i>Journal of Clinical Lipidology</i> , 2018, 12, 728-733.	0.6	12

#	ARTICLE	IF	CITATIONS
19	Risk Factors and Trends in Incidence of Heart Failure Following Acute Myocardial Infarction. American Journal of Cardiology, 2018, 122, 1-5.	0.7	31
20	Blood pressure is a beautiful (but imperfect) biomarker of hypertension. The quixotic quest that fuels the hypertension guideline industry. Journal of Clinical Hypertension, 2018, 20, 840-841.	1.0	5
21	Quality of Meta-Analyses for Randomized Trials in the Field of Hypertension: an Updated and Improved Systematic Review. Current Hypertension Reports, 2017, 19, 71.	1.5	2
22	Visit-to-visit variability of blood pressure. Journal of the American Society of Hypertension, 2017, 11, 473-474.	2.3	0
23	HOPE-3 and SPRINT: two landmark trials with different outcomes?. Journal of the American Society of Hypertension, 2016, 10, 477-481.	2.3	1
24	Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years. JAMA - Journal of the American Medical Association, 2016, 315, 2673.	3.8	991
25	Angioedema with renin angiotensin system drugs and neutral endopeptidase inhibitors. Journal of the American Society of Hypertension, 2016, 10, 387-389.	2.3	6
26	Statin Use and Risk of Cataract Response to Letter. Journal of Cardiovascular Pharmacology and Therapeutics, 2016, 21, 223-223.	1.0	0
27	Response to Letter on "Statin Use and Risk of Cataracts. Journal of Cardiovascular Pharmacology and Therapeutics, 2015, 20, 346-347.	1.0	4
28	Radiation-Induced Heart Disease: Pathologic Abnormalities and Putative Mechanisms. Frontiers in Oncology, 2015, 5, 39.	1.3	232
29	Erectile Dysfunction Is Common among Patients with Gout. Journal of Rheumatology, 2015, 42, 1893-1897.	1.0	26
30	Statins and Cataracts—a Visual Insight. Current Atherosclerosis Reports, 2015, 17, 477.	2.0	14
31	Pharmacologic Therapy for Erectile Dysfunction and its Interaction With the Cardiovascular System. Journal of Cardiovascular Pharmacology and Therapeutics, 2014, 19, 53-64.	1.0	22
32	Statin Use and Cataract. JAMA Ophthalmology, 2014, 132, 363.	1.4	4
33	All Men with Vasculogenic Erectile Dysfunction Require a Cardiovascular Workup. American Journal of Medicine, 2014, 127, 174-182.	0.6	74
34	Visit-to-Visit Blood Pressure Variability and Cardiovascular Death in the Systolic Hypertension in the Elderly Program. Journal of Clinical Hypertension, 2014, 16, 34-40.	1.0	29
35	The Effect of Statins on Erectile Dysfunction: A Meta-Analysis of Randomized Trials. Journal of Sexual Medicine, 2014, 11, 1626-1635.	0.3	55
36	Competing Cardiovascular and Noncardiovascular Risks and Longevity in the Systolic Hypertension in the Elderly Program. American Journal of Cardiology, 2014, 113, 676-681.	0.7	9

#	ARTICLE	IF	CITATIONS
37	The Princeton III Consensus Recommendations for the Management of Erectile Dysfunction and Cardiovascular Disease. Mayo Clinic Proceedings, 2012, 87, 766-778.	1.4	403
38	Continuation of mortality reduction after the end of randomized therapy in clinical trials of lipid-lowering therapy. Journal of Clinical Lipidology, 2011, 5, 97-104.	0.6	20
39	Association Between Chlorthalidone Treatment of Systolic Hypertension and Long-term Survival. JAMA - Journal of the American Medical Association, 2011, 306, 2588.	3.8	68
40	Antihypertensive Therapy With CCB/ARB Combination in Older Individuals: Focus on Amlodipine/Valsartan Combination. American Journal of Therapeutics, 2010, 17, 188-196.	0.5	9
41	Differences Among ACE Inhibitors. American Journal of Hypertension, 2010, 23, 1156-1156.	1.0	2
42	The Benefits of Intensive Lipid Lowering in Patients With Stable Coronary Heart Disease With Normal or High Systolic Blood Pressure: An Analysis of the Treating to New Targets (TNT) Study. Journal of Clinical Hypertension, 2008, 10, 367-376.	1.0	13
43	Response to Letter by Bath et al. Stroke, 2008, 39, .	1.0	0
44	A New Approach to Primary Prevention of Cardiovascular Disease. American Journal of Medicine, 2007, 120, 746-747.	0.6	9
45	The Importance of Managing Hypertension and Dyslipidemia to Decrease Cardiovascular Disease. Cardiovascular Drugs and Therapy, 2007, 21, 297-309.	1.3	49
46	Disputation on the Use of Age in Determining the Need for Treatment of Hypercholesterolemia and Hypertension. Journal of Clinical Hypertension, 2006, 8, 519-520.	1.0	8
47	Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. American Journal of Cardiology, 2005, 95, 29-35.	0.7	320
48	Sexual Dysfunction and Cardiac Risk (the Second Princeton Consensus Conference). American Journal of Cardiology, 2005, 96, 85-93.	0.7	112
49	Hypertension: Definitions and Guidelines. Journal of Clinical Hypertension, 2005, 7, 538-539.	1.0	7
50	International medical graduates and the cardiology workforce. Journal of the American College of Cardiology, 2004, 44, 1172-1174.	1.2	7
51	Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. American Journal of Hypertension, 2004, 17, 103-111.	1.0	492
52	From hypertension to heart failure: update on the management of systolic and diastolic dysfunction. American Journal of Hypertension, 2003, 16, 18-22.	1.0	18
53	Treatment of Hypertension in Older Patients: An Updated Look at the Role of Calcium Antagonists. The American Journal of Geriatric Cardiology, 2003, 12, 319-327.	0.7	11
54	Comparison of Pharmacokinetics of Lanoteplase and Alteplase During Acute Myocardial Infarction. Clinical Pharmacokinetics, 2002, 41, 445-452.	1.6	13

#	ARTICLE	IF	CITATIONS
55	Effect of anemia on 1-year mortality in patients with acute myocardial infarction. American Heart Journal, 2002, 144, 636-641.	1.2	88
56	Association of angiotensin-converting enzyme DD genotype with blood pressure sensitivity to weight loss. American Heart Journal, 2002, 144, 625-629.	1.2	6
57	Effect of anemia on 1-year mortality in patients with acute myocardial infarction. American Heart Journal, 2002, 144, 636-641.	1.2	101
58	Hemostatic Function and Coronary Artery Disease. Circulation, 2000, 101, E195.	1.6	0
59	The cost and cardioprotective effects of enalapril in hypertensive patients with left ventricular dysfunction. American Journal of Hypertension, 1998, 11, 1433-1441.	1.0	18
60	Fosinopril: Pharmacokinetics and pharmacodynamics in congestive heart failure*. Clinical Pharmacology and Therapeutics, 1995, 58, 660-665.	2.3	19
61	Central Nervous System Effects of HMG CoA Reductase Inhibitors: Lovastatin and Pravastatin on Sleep and Cognitive Performance in Patients with Hypercholesterolemia. Journal of Clinical Pharmacology, 1994, 34, 989-996.	1.0	70
62	The effect of treatment on survival in congestive heart failure. Clinical Cardiology, 1992, 15, 323-329.	0.7	11
63	Angiotensin Converting Enzyme Inhibitors in Hypertension. Cardiovascular Drug Reviews, 1989, 7, 173-176.	4.4	4
64	Percutaneous transluminal coronary angioplasty in situs inversus. Catheterization and Cardiovascular Diagnosis, 1987, 13, 114-116.	0.7	39